Innovative Diagnostic Tool Accelerates Identification of Rare Genetic Diseases in Children
A new proteomics-based diagnostic test is revolutionizing the detection of rare genetic diseases in children, reducing diagnosis time from weeks to days and improving outcomes for affected families.
The process of diagnosing rare genetic diseases in children has historically been lengthy and challenging, often involving numerous tests, hospital visits, and specialist consultations. Despite the definition of "rare" implying infrequent occurrence, these conditions collectively impact approximately 2 million Australians, equating to around 8% of the population. Advances in genomics have improved diagnostic rates, with about half of affected families receiving answers within months. However, many still face a protracted "diagnostic odyssey," undergoing invasive and time-consuming tests that may not conclusively identify the disease.
To address this, researchers at the University of Melbourne have developed a groundbreaking diagnostic test that works in tandem with genome sequencing data. Published in Genome Medicine, this proteomics-based test enables rapid interpretation of genetic variants by analyzing proteins in the blood, offering results in as little as three days—an improvement over the weeks or months traditional methods require.
This innovative test is not limited to a specific disorder but covers thousands of known disease-causing mutations, providing a scalable and cost-effective alternative to multiple functional tests. It is particularly effective in neonatal intensive care units, facilitating early diagnosis in critically ill infants.
A poignant example of its impact is the case of a family who lost their first child due to mitochondrial disease. Utilizing stored samples, clinicians confirmed the genetic diagnosis swiftly, enabling prenatal testing in subsequent pregnancies. This allowed the birth of a healthy child and exemplifies how early, accurate diagnosis can prevent family grief and enable informed reproductive choices.
Looking ahead, the team is recruiting additional patients to validate the test's utility across various genetic conditions. The ultimate goal is to integrate this technology into national healthcare services, making quick and affordable diagnosis accessible to as many families as possible.
This development marks a significant step forward in reducing the diagnostic burden and improving outcomes for children with rare genetic conditions.
Source: https://medicalxpress.com/news/2025-05-diagnosis-journey-children-born-rare.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
groundbreaking trial demonstrates success of Satri-cel CAR T-cell therapy in treating solid tumors
A groundbreaking clinical trial demonstrates that Satri-cel, a targeted CAR T-cell therapy, significantly extends survival in patients with advanced gastric cancers, marking a major milestone in solid tumor immunotherapy.
Innovative Approach Using Iron to Target Multiple Myeloma Cells
Duke University researchers have discovered that inhibiting the enzyme STK17B can trigger ferroptosis in multiple myeloma cells, offering a new promising treatment strategy to overcome drug resistance and improve outcomes for patients.
Innovative Treatment Shows Promise in Reducing Brain Damage Post-Stroke in Mice
Cambridge researchers have developed a promising drug that significantly reduces brain damage from stroke in mouse models, offering hope for improved treatment outcomes in humans. The innovative approach targets free radical formation during reperfusion, potentially revolutionizing stroke therapy.